Home / Health / India Eyes Stricter Rules on Pharmaceutical Brand Names
India Eyes Stricter Rules on Pharmaceutical Brand Names
10 Jul
Summary
- Regulator proposes restricting same brand name for different drug ingredients.
- Practice can mislead patients and create confusion over drug use.
- Public comments invited on the proposal until July 17.
The Central Drugs Standard Control Organisation (CDSCO) in India is moving to enhance patient safety by proposing restrictions on using identical brand names for medicines containing disparate active ingredients. This initiative stems from concerns that such practices can significantly mislead patients and cause confusion regarding the intended therapeutic applications of medications.
Currently, the regulatory body has extended an invitation for public comments on this proposal, with submissions due by July 17. The proposal follows numerous representations highlighting instances where pharmaceutical firms market different active ingredients under well-established brand names. The Drugs Consultative Committee (DCC) has examined this issue and recommended broad stakeholder consultation prior to any definitive action.
Experts like Dr. Neeraj Nischal from AIIMS emphasize that while umbrella branding can build company recognition, its extension to medicines with different active ingredients or fixed-dose combinations poses a serious risk. This can directly lead to errors in prescribing, dispensing, and patient usage. Such practices are acceptable only when different strengths or formulations of the same active ingredient share a brand, but unrelated drugs under one parent brand heighten medication risks.
Dr. Rommel Tickoo of Max Super Speciality Hospital, Saket, supports the initiative, stating a brand name should distinctly represent a specific medicine. He advocates for a phased implementation following thorough stakeholder discussions to manage the transition for pharmaceutical companies that may need to revise branding strategies for products across various therapeutic categories marketed under a common parent brand.
